Categories: HealthTechITLearnMovingPlatform
Diagonal Therapeutics pioneers a new era in medicine by advancing clustering antibody therapeutics targeting the root causes of devastating diseases.
Investors 2
Mentions in press and media 5
| Date | Title | Description |
| 11.01.2026 | Diagonal Therapeutics Secures $125M to Propel Innovative Antibody Therapies | Diagonal Therapeutics secured $125M Series B funding. This advances DIAG723, a first-in-class clustering antibody. It targets hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH). The Watertown biotech corre... |
| 09.01.2026 | Diagonal Therapeutics Raises $125M in Series B Financing | Diagonal Therapeutics, a Watertown, MA-based biotechnology company developing disease-modifying clustering antibodies that correct dysregulated signaling in severe genetic diseases, raised $125M in Series B Funding.
The round was co-led by ... |
| 04.04.2024 | Diagonal Therapeutics Launches with $128 Million in Financing | Diagonal Therapeutics, a Cambridge, MA-based biotechnology company developing new approach to discovering agonist antibodies, raised $128M in funding.
The round was co-led by BVF Partners and Atlas Venture, with participation from Lightspee... |
| - | Diagonal Therapeutics | “Diagonal Therapeutics pioneers a new era in medicine by advancing agonist antibody therapeutics targeting the root causes of devastating diseases. Discover our ground-breaking approach to reactivate critical biological pathways for transfo... |
| - | Diagonal Therapeutics | “Diagonal Therapeutics pioneers a new era in medicine by advancing clustering antibody therapeutics targeting the root causes of devastating diseases.” |
Reviews 0
